Hikma Pharmaceuticals

Summary

History

Mission

Vision

References

Summary

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

History

The company was founded in 1978 by Samih Darwazah in Amman, Jordan. In August 1996 it became the first Arab company to export pharmaceutical products to the United States. It was first listed on the London Stock Exchange in 2005. Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005 and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006. In 2007 the Company went on to buy APM in Jordan, Alkan Pharma in Egypt, APM and Al Jazeera Pharma in Saudi Arabia, Thymoorgan in Germany, and Ribosepharm in Germany. It started to acquire Baxter Healthcare Corporation's US generic injectables business, Multi-Source Injectables or MSI, and completed the transaction in May 2011.In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco. Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma’s second venture in Algeria after Hikma Pharma Algeria.In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company.Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries in 2012. In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement with MIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market.On 28 May 2014, Hikma Pharmaceuticals agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.In June 2020, Boehringer announced it would sell off part of its stake in London-listed Hikma Pharmaceuticals for around $800 million.

Mission

A healthier world that enriches all of our communities

Vision

Our vision is of a healthier world that enriches all of our communities. Throughout our last 40 years, we've been guided by the simple belief that when world-class medicine is put within people's reach, it has the ability to transform their lives and their communities.Today at Hikma we now have the reach, insight and expertise to transform so many more people's lives.And in a fast-changing world, our commitment to our vision is as important as ever - not only for Hikma, but also for the millions of people we serve around the world.

References

https://en.wikipedia.org/wiki/Hikma_Pharmaceuticals

https://in.investing.com/equities/hikma-pharmaceuticals

https://finance.yahoo.com/quote/HIK.L/profile?p=HIK.L

https://www.comparably.com/companies/hikma-pharmaceuticals/mission

https://www.crunchbase.com/organization/hikma-pharmaceuticals

https://companiesmarketcap.com/

https://www.hikma.com

Leadership team

Engineer Said Samih Taleb Darwazah (Exec. Chairman & CEO)

Mr. Mazen Samih Taleb Darwazah (Exec. Vice Chairman & Pres of MENA)

Mr. Khalid Waleed Hosny Al Nabilsi (Chief Financial Officer)